CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial
| Autor: | Lancet, Jeffrey E *, Uy, Geoffrey L, Newell, Laura F, Lin, Tara L, Ritchie, Ellen K, Stuart, Robert K, Strickland, Stephen A, Hogge, Donna, Solomon, Scott R, Bixby, Dale L, Kolitz, Jonathan E, Schiller, Gary J, Wieduwilt, Matthew J, Ryan, Daniel H, Faderl, Stefan, Cortes, Jorge E |
|---|---|
| Zdroj: | In The Lancet Haematology July 2021 8(7):e481-e491 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|